David Hedley - Publications

University of Toronto, Toronto, ON, Canada 
Medical Biophysics

82 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Gendoo DMA, Denroche RE, Zhang A, Radulovich N, Jang GH, Lemire M, Fischer S, Chadwick D, Lungu IM, Ibrahimov E, Cao PJ, Stein LD, Wilson JM, Bartlett JMS, Tsao MS, ... ... Hedley D, et al. Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. Plos Computational Biology. 15: e1006596. PMID 30629588 DOI: 10.1371/Journal.Pcbi.1006596  0.56
2017 Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, et al. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clinical Colorectal Cancer. PMID 29128266 DOI: 10.1016/J.Clcc.2017.10.010  0.56
2016 MacLaughlin CM, Ding L, Jin C, Cao P, Siddiqui I, Hwang DM, Chen J, Wilson BC, Zheng G, Hedley DW. Porphysome nanoparticles for enhanced photothermal therapy in a patient-derived orthotopic pancreas xenograft cancer model: a pilot study. Journal of Biomedical Optics. 21: 84002. PMID 27552306 DOI: 10.1117/1.Jbo.21.8.084002  0.6
2016 Lohse I, Rasowski J, Cao P, Pintilie M, Do T, Tsao MS, Hill RP, Hedley DW. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302. Oncotarget. PMID 27248663 DOI: 10.18632/Oncotarget.9654  0.56
2016 Chang Q, Chandrashekhar M, Ketela T, Fedyshyn Y, Moffat J, Hedley D. Cytokinetic effects of Wee1 disruption in pancreatic cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 26890070 DOI: 10.1080/15384101.2016.1138188  0.6
2016 Metran-Nascente C, Yeung I, Vines D, Metser U, Dhani N, Green D, Milosevic M, Jaffray D, Hedley D. Measurement of tumor hypoxia in patients with advanced pancreatic cancer based on 18F-fluoroazomyin arabinoside (18F-FAZA) uptake. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26769863 DOI: 10.2967/Jnumed.115.167650  0.6
2015 Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. British Journal of Cancer. 113: 425-32. PMID 26180923 DOI: 10.1038/bjc.2015.220  0.6
2015 How C, Bruce J, So J, Pintilie M, Haibe-Kains B, Hui A, Clarke BA, Hedley DW, Hill RP, Milosevic M, Fyles A, Liu FF. Chromosomal instability as a prognostic marker in cervical cancer. Bmc Cancer. 15: 361. PMID 25944123 DOI: 10.1186/S12885-015-1372-0  0.6
2015 Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, Gallinger S. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 25940717 DOI: 10.1200/Jco.2014.59.7401  0.6
2015 How C, Pintilie M, Bruce JP, Hui AB, Clarke BA, Wong P, Yin S, Yan R, Waggott D, Boutros PC, Fyles A, Hedley DW, Hill RP, Milosevic M, Liu FF. Developing a prognostic micro-RNA signature for human cervical carcinoma. Plos One. 10: e0123946. PMID 25880806 DOI: 10.1371/Journal.Pone.0123946  0.6
2015 Ernsting MJ, Hoang B, Lohse I, Undzys E, Cao P, Do T, Gill B, Pintilie M, Hedley D, Li SD. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. Journal of Controlled Release : Official Journal of the Controlled Release Society. 206: 122-30. PMID 25804872 DOI: 10.1016/J.Jconrel.2015.03.023  0.6
2015 Dhani N, Fyles A, Hedley D, Milosevic M. The clinical significance of hypoxia in human cancers. Seminars in Nuclear Medicine. 45: 110-21. PMID 25704384 DOI: 10.1053/J.Semnuclmed.2014.11.002  0.6
2015 Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments. Nuclear Medicine and Biology. 42: 71-7. PMID 25456837 DOI: 10.1016/J.Nucmedbio.2014.10.009  0.6
2015 Chang Q, Ornatsky OI, Koch CJ, Chaudary N, Marie-Egyptienne DT, Hill RP, Tanner SD, Hedley DW. Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry. International Journal of Cancer. Journal International Du Cancer. 136: 1202-9. PMID 25042623 DOI: 10.1002/Ijc.29074  0.6
2014 Edgar LJ, Vellanki RN, Halupa A, Hedley D, Wouters BG, Nitz M. Identification of hypoxic cells using an organotellurium tag compatible with mass cytometry. Angewandte Chemie (International Ed. in English). 53: 11473-7. PMID 25195589 DOI: 10.1002/Anie.201405233  0.6
2014 Lohse I, Lourenco C, Ibrahimov E, Pintilie M, Tsao MS, Hedley DW. Assessment of hypoxia in the stroma of patient-derived pancreatic tumor xenografts. Cancers. 6: 459-71. PMID 24577243 DOI: 10.3390/cancers6010459  0.56
2014 Watson M, Chow S, Barsyte D, Arrowsmith C, Shankey TV, Minden M, Hedley D. The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytometry. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 85: 78-87. PMID 24038859 DOI: 10.1002/Cyto.A.22344  0.6
2014 Milosevic MF, Pintilie M, Hedley DW, Bristow RG, Wouters BG, Oza AM, Laframboise S, Hill RP, Fyles AW. High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. International Journal of Cancer. Journal International Du Cancer. 135: 1692-9. PMID 23904154 DOI: 10.1002/Ijc.28403  0.6
2013 McNamara MG, Walter T, Horgan AM, Amir E, Cleary S, McKeever EL, Min T, Wallace E, Hedley D, Krzyzanowska M, Moore M, Gallinger S, Greig P, Serra S, Dawson LA, et al. Outcome of Adjuvant Therapy in Biliary Tract Cancers. American Journal of Clinical Oncology. PMID 24572429 DOI: 10.1097/Coc.0B013E31829E19Fb  0.6
2013 How C, Hui AB, Alajez NM, Shi W, Boutros PC, Clarke BA, Yan R, Pintilie M, Fyles A, Hedley DW, Hill RP, Milosevic M, Liu FF. MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. Plos One. 8: e67846. PMID 23861821 DOI: 10.1371/Journal.Pone.0067846  0.6
2013 Chang Q, Foltz WD, Chaudary N, Hill RP, Hedley DW. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. International Journal of Cancer. Journal International Du Cancer. 133: 225-34. PMID 23280784 DOI: 10.1002/Ijc.28006  0.6
2013 Xu J, Knox JJ, Ibrahimov E, Chen E, Serra S, Tsao M, Cao P, Vines D, Green DE, Metran-Nascente C, McNamara MG, Hedley DW. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer Clinical Cancer Research. 19: 118-127. PMID 23091117 DOI: 10.1158/1078-0432.Ccr-12-2557  0.6
2012 Xu J, Knox JJ, Tsao MS, Chen EX, Cao P, Sue C, Serra S, Hedley DW. Preclinical study of MEK1/2 inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 240. PMID 27982965 DOI: 10.1200/jco.2012.30.4_suppl.240  0.56
2012 Mamaghani S, Simpson CD, Cao PM, Cheung M, Chow S, Bandarchi B, Schimmer AD, Hedley DW. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. Plos One. 7: e41102. PMID 22829912 DOI: 10.1371/journal.pone.0041102  0.6
2012 Chang Q, Hedley D. Emerging applications of flow cytometry in solid tumor biology. Methods (San Diego, Calif.). 57: 359-67. PMID 22503773 DOI: 10.1016/J.Ymeth.2012.03.027  0.6
2012 Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs. 30: 779-86. PMID 21170669 DOI: 10.1007/S10637-010-9611-3  0.6
2011 Brandwein JM, Hedley DW, Chow S, Schimmer AD, Yee KWL, Schuh AC, Gupta V, Xu W, Kamel-Reid S, Minden MD. A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: Inhibition of Akt activation correlates with complete response Leukemia. 25: 945-952. PMID 21403650 DOI: 10.1038/Leu.2011.34  0.6
2011 Wong KM, Khanna M, Wu RC, Hedley DW. Gemcitabine-induced acute myositis in a patient with duodenal cancer. Clinical Oncology (Royal College of Radiologists (Great Britain)). 23: 492-3. PMID 21376549 DOI: 10.1016/j.clon.2011.02.007  0.6
2011 Chang Q, Jurisica I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Research. 71: 3110-20. PMID 21343390 DOI: 10.1158/0008-5472.Can-10-4049  0.6
2011 You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicacio LV, Chen EX. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies Investigational New Drugs. 29: 996-1003. PMID 20454832 DOI: 10.1007/S10637-010-9444-0  0.6
2010 Chang Q, Chapman MS, Miner JN, Hedley DW. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. Bmc Cancer. 10: 515. PMID 20920162 DOI: 10.1186/1471-2407-10-515  0.6
2010 Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia & Lymphoma. 51: 252-60. PMID 20109071 DOI: 10.3109/10428190903585286  0.6
2010 Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. American Journal of Clinical Oncology. 33: 609-13. PMID 20042973 DOI: 10.1097/Coc.0B013E3181Beac33  0.6
2009 Ito E, Yip KW, Katz D, Fonseca SB, Hedley DW, Chow S, Xu GW, Wood TE, Bastianutto C, Schimmer AD, Kelley SO, Liu FF. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Molecular Pharmacology. 76: 969-83. PMID 19654225 DOI: 10.1124/Mol.109.055277  0.6
2009 Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4741-6. PMID 19652057 DOI: 10.1200/Jco.2009.21.8172  0.6
2009 Lo M, Tsao MS, Hedley D, Ling V. Gene expression profiling of adenosine triphosphate-binding cassette transporters in response to K-ras activation and hypoxia in human pancreatic cancer cell cultures. Pancreas. 38: 85-93. PMID 19117087 DOI: 10.1097/Mpa.0B013E318184Aa8A  0.6
2009 Chow S, Nagai M, He S, Blackman RK, Barsoum J, Vukovic V, Hedley D. Antileukemic Effects of the Novel Agent Elesclomol. Blood. 114: 2736-2736. DOI: 10.1182/Blood.V114.22.2736.2736  0.6
2008 Mao X, Liang SB, Hurren R, Gronda M, Chow S, Xu GW, Wang X, Beheshti Zavareh R, Jamal N, Messner H, Hedley DW, Datti A, Wrana JL, Zhu Y, Shi CX, et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 112: 760-9. PMID 18502826 DOI: 10.1182/blood-2008-02-142687  0.6
2008 Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW, Tsao MS. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. Bmc Cancer. 8: 43. PMID 18254976 DOI: 10.1186/1471-2407-8-43  0.56
2007 Pham NA, Tsao MS, Cao P, Hedley DW. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pancreas. 35: e16-26. PMID 17895832 DOI: 10.1097/Mpa.0B013E318095A747  0.56
2007 Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2184-90. PMID 17538163 DOI: 10.1200/Jco.2006.07.6554  0.6
2007 Zogopoulos G, Rothenmund H, Eppel A, Ash C, Akbari MR, Hedley D, Narod SA, Gallinger S. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Human Genetics. 121: 635-7. PMID 17415588 DOI: 10.1007/S00439-007-0361-Z  0.6
2007 Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, Ho J, Hedley DW. Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagnostic Pathology. 2: 8. PMID 17326824 DOI: 10.1186/1746-1596-2-8  0.56
2006 Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, Liu FF. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5557-69. PMID 17000693 DOI: 10.1158/1078-0432.Ccr-06-0536  0.6
2006 Yip KW, Ito E, Mao X, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, Liu FF. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Molecular Cancer Therapeutics. 5: 2234-40. PMID 16985057 DOI: 10.1158/1535-7163.Mct-06-0134  0.6
2006 Gurfinkel DM, Chow S, Hurren R, Gronda M, Henderson C, Berube C, Hedley DW, Schimmer AD. Disruption of the endoplasmic reticulum and increases in cytoplasmic calcium are early events in cell death induced by the natural triterpenoid Asiatic acid. Apoptosis : An International Journal On Programmed Cell Death. 11: 1463-71. PMID 16820960 DOI: 10.1007/s10495-006-9086-z  0.6
2005 Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Annals of the New York Academy of Sciences. 1059: 184-95. PMID 16382054 DOI: 10.1196/Annals.1339.049  0.6
2005 Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8782-8. PMID 16361566 DOI: 10.1158/1078-0432.Ccr-05-1664  0.6
2005 Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5526-33. PMID 16061869 DOI: 10.1158/1078-0432.Ccr-05-0081  0.6
2005 Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Research. 65: 1497-504. PMID 15735038 DOI: 10.1158/0008-5472.CAN-04-2940  0.6
2005 Hedley DW, Nicklee T, Moreno-Merlo F, Pintilie M, Fyles A, Milosevic M, Hill RP. Relations between non-protein sulfydryl levels in the nucleus and cytoplasm, tumor oxygenation, and clinical outcome of patients with uterine cervical carcinoma. International Journal of Radiation Oncology, Biology, Physics. 61: 137-44. PMID 15629604 DOI: 10.1016/j.ijrobp.2004.02.020  0.6
2004 Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Molecular Cancer Therapeutics. 3: 1239-48. PMID 15486191  0.6
2004 Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Molecular and Cellular Biology. 24: 8504-18. PMID 15367671 DOI: 10.1128/Mcb.24.19.8504-8518.2004  0.6
2004 Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Seminars in Radiation Oncology. 14: 249-58. PMID 15254868 DOI: 10.1016/J.Semradonc.2004.04.006  0.6
2004 Måseide K, Kandel RA, Bell RS, Catton CN, O'Sullivan B, Wunder JS, Pintilie M, Hedley D, Hill RP. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4464-71. PMID 15240538 DOI: 10.1158/1078-0432.Ccr-03-0541  0.6
2004 Hedley D, Pintilie M, Woo J, Nicklee T, Morrison A, Birle D, Fyles A, Milosevic M, Hill R. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. The American Journal of Pathology. 164: 557-65. PMID 14742261 DOI: 10.1016/S0002-9440(10)63145-8  0.6
2003 Yee KW, Moore SJ, Midmer M, Zanke BW, Tong F, Hedley D, Minden MD. NKIAMRE, a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases. Biochemical and Biophysical Research Communications. 308: 784-92. PMID 12927787 DOI: 10.1016/S0006-291X(03)01475-X  0.6
2002 Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Molecular Cancer Therapeutics. 1: 777-83. PMID 12492110  0.6
2002 Lin Y, Brown L, Hedley DW, Barber DL, Benchimol S. The death-promoting activity of p53 can be inhibited by distinct signaling pathways. Blood. 100: 3990-4000. PMID 12393587 DOI: 10.1182/Blood-2002-02-0504  0.6
2002 Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP, Hedley DW. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. International Journal of Radiation Oncology, Biology, Physics. 53: 854-61. PMID 12095550 DOI: 10.1016/S0360-3016(02)02815-8  0.6
2002 Vukovic V, Nicklee T, Hedley DW. Multiparameter fluorescence mapping of nonprotein sulfhydryl status in relation to blood vessels and hypoxia in cervical carcinoma xenografts. International Journal of Radiation Oncology, Biology, Physics. 52: 837-43. PMID 11849809 DOI: 10.1016/S0360-3016(01)02716-X  0.6
2001 Vukovic V, Haugland HK, Nicklee T, Morrison AJ, Hedley DW. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Research. 61: 7394-8. PMID 11606368  0.6
2001 Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3269-75. PMID 11595724  0.6
2001 Constantinou P, Vukovic V, Haugland HK, Nicklee T, Hedley DW, Wilson BC. Imaging of whole tumor cut sections using a novel scanning beam confocal fluorescence MACROscope. Journal of Biomedical Optics. 6: 326-31. PMID 11516323 DOI: 10.1117/1.1383779  0.6
2001 Vukovic V, Nicklee T, Hedley DW. Differential effects of buthionine sulphoximine in hypoxic and non-hypoxic regions of human cervical carcinoma xenografts. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 60: 69-73. PMID 11410306 DOI: 10.1016/S0167-8140(01)00331-0  0.6
2000 Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Research. 60: 5451-5. PMID 11034087  0.56
2000 Vukovic V, Pheng SR, Stewart A, Vik CH, Hedley DW. Protection from radiation-induced DNA single-strand breaks by induction of nuclear metallothionein. International Journal of Radiation Biology. 76: 757-62. PMID 10902729 DOI: 10.1080/09553000050028904  0.6
2000 Vukovic V, Nicklee T, Hedley DW. Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 1826-32. PMID 10815904  0.6
1996 Nicklee T, Crump M, Hedley DW. Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry. Cytometry. 25: 205-10. PMID 8914817 DOI: 10.1002/(SICI)1097-0320(19961101)25:3<205::AID-CYTO1>3.0.CO;2-E  0.6
1995 Pressacco J, Wiley JS, Jamieson GP, Erlichman C, Hedley DW. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. British Journal of Cancer. 72: 939-42. PMID 7547244 DOI: 10.1038/bjc.1995.437  0.6
1994 Brezden CB, Hedley DW, Rauth AM. Constitutive expression of P-glycoprotein as a determinant of loading with fluorescent calcium probes. Cytometry. 17: 343-8. PMID 7875042 DOI: 10.1002/cyto.990170411  0.6
1993 Boyer MJ, Barnard M, Hedley DW, Tannock IF. Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours British Journal of Cancer. 68: 890-897. PMID 8217605 DOI: 10.1038/Bjc.1993.451  0.6
1988 Friedlander ML, Hedley DW, Swanson C, Russell P. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer Journal of Clinical Oncology. 6: 282-290. PMID 3276825 DOI: 10.1200/JCO.1988.6.2.282  0.6
1987 Musgrove E, Seaman M, Hedley D. Relationship between cytoplasmic pH and proliferation during exponential growth and cellular quiescence Experimental Cell Research. 172: 65-75. PMID 3653258 DOI: 10.1016/0014-4827(87)90093-0  0.6
1987 DeFazio A, Leary JA, Hedley DW, Tattersall MHN. Immunohistochemical detection of proliferating cells in vivo Journal of Histochemistry and Cytochemistry. 35: 571-577. PMID 3549891 DOI: 10.1177/35.5.3549891  0.6
1985 Hedley DW, Friedlander ML, Taylor IW. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance Cytometry. 6: 327-333. PMID 4017799 DOI: 10.1002/cyto.990060409  0.6
1985 Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: Abnormalities of cellular DNA content and survival European Journal of Cancer and Clinical Oncology. 21: 185-189. PMID 3987755 DOI: 10.1016/0277-5379(85)90171-3  0.6
1984 Friedlander ML, Russell P, Taylor IW, Hedley DW, Tattersall MHN. Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy Pathology. 16: 301-306. PMID 6514398 DOI: 10.3109/00313028409068541  0.6
1984 Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. DNA flow cytometry of paraffin-embedded tissue Cytometry. 5: 660. PMID 6394250 DOI: 10.1002/cyto.990050618  0.6
1984 Friedlander ML, Hedley DW, Taylor IW. Clinical and biological significance of aneuploidy in human tumours Journal of Clinical Pathology. 37: 961-974. PMID 6381555 DOI: 10.1136/jcp.37.9.961  0.6
1983 Taylor IW, Musgrove EA, Friedlander ML, Foo MS, Hedley DW. The influence of age on the DNA ploidy levels of breast tumours European Journal of Cancer and Clinical Oncology. 19: 623-628. PMID 6683634 DOI: 10.1016/0277-5379(83)90178-5  0.6
1983 Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry Journal of Histochemistry and Cytochemistry. 31: 1333-1335. PMID 6619538 DOI: 10.1177/31.11.6619538  0.6
Show low-probability matches.